Published on
19:45 GMT
Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC
The FDA has recently approved AstraZeneca’s Imfinzi (durvalumab) for perioperative use in cisplatin-eligible muscle-invasive bladder cancer (MIBC), based on the Phase III NIAGARA trial. With its practice-changing regimen, Imfinzi is the first immunotherapy …
Source:
Clinical Trials Arena
-
Pending
